23andMe Holding Co. (ME) EPS Basic: -9.05
Is 23andMe Holding Co.’s EPS basic high or low?
23andMe Holding Co.'s EPS basic of -9.05 is 36% above its 5-year average of -14.25, near the high end of its 5-year range (-27.59–-9.02).
52.95% above its 12-month average of -19.23.
ME EPS Basic Chart
ME Average EPS Basic Chart
ME Current vs Average EPS Basic Chart
ME EPS Basic Metrics
EPS BASIC
-9.05
EPS BASIC AVG TTM
-19.23
EPS BASIC AVG 3Y
-15.56
EPS BASIC AVG 5Y
-14.25
EPS BASIC AVG 10Y
N/A
EPS BASIC AVG 15Y
N/A
EPS BASIC AVG 20Y
N/A
CURRENT VS TTM AVG
+52.95%
CURRENT VS 3Y AVG
+41.84%
CURRENT VS 5Y AVG
+36.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
23andMe Holding Co. EPS Basic Formula & Definition
EPS Basic is earnings per common share before the effect of potentially dilutive securities. It shows how much profit is attributable to each current common share.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. EPS Basic FAQ
- What is the EPS basic for 23andMe Holding Co. (ME)?
- The EPS basic for ME stock is -9.05.
- Is 23andMe Holding Co.'s EPS basic high or low?
- 23andMe Holding Co.'s EPS basic of -9.05 is 36% above its 5-year average of -14.25, near the high end of its 5-year range (-27.59–-9.02).
- What is the TTM average EPS basic for 23andMe Holding Co. (ME)?
- The TTM average EPS basic for ME stock is -19.23.
- What is the 3Y average EPS basic for 23andMe Holding Co. (ME)?
- The 3Y average EPS basic for ME stock is -15.56.
- What is the 5Y average EPS basic for 23andMe Holding Co. (ME)?
- The 5Y average EPS basic for ME stock is -14.25.
23andMe Holding Co. EPS Basic History
| DATE | EPS BASIC |
|---|---|
| 2025-03-31 | -10.88 |
| 2024-03-31 | -27.59 |
| 2023-03-31 | -13.81 |
| 2022-03-31 | -9.96 |
| 2021-03-31 | -9.02 |
| 2020-03-31 | -14.24 |
| 2019-03-31 | -9.03 |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage